公司研究 [Table_ReportType] 公司点评报告 [华Ta康bl股e_份Sto(c6k0A5n0d7Ra7n)k] 上次评级 赵 雷 食品饮料行业分析师 执业编号：S1500524100003 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲 127 号 金隅大厦 B 座 邮编：100031 [ 资 T 料 ab 来 l 源 e_ ： RWepinodr ， t 信 Cl 达 o 证 si 券 n 研 g] 发中心预测 ; 股价为 2025 年 8 月 26 日收盘价 请阅读最后一页免责声明及信息披露 http://www.cindasc.com 2 证券研究报告 [Table_Title] 利润短期承压，关注反转催化 [Table_ReportDate] 2025 年 8 月 27 日 投资评级 [T事ab件le：_S公um司ma公ry布] 2025 年半年报。25H1，公司实现营业收入 18.66 亿元， 同比+37.32%，归母净利润 1.34 亿元，同比-3.38%；扣非归母净利润 1.22 亿元，同比-6.56%。其中，25Q2 公司实现 ...

| 证券代码：605077 | 证券简称：华康股份 | 公告编号：2025-070 | | --- | --- | --- | | 债券代码：111018 | 债券简称：华康转债 | | 浙江华康药业股份有限公司 关于 2025 年半年度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号—行业信息披露》（第 十四号—食品制造）相关规定，现将浙江华康药业股份有限公司（以下简称"公司"） 2025 年半年度主要经营数据公告如下： 一、2025 年半年度主要经营数据 1、按照产品类别分类情况 | | 单位：万元 币种：人民币 | | --- | --- | | 产品类别 | 2025 年半年度营业收入 | | 晶体糖醇产品 | 101,422.10 | | 液体糖、醇及其他产品 | 60,548.00 | | 其他 | 24,588.68 | | 合计 | 186,558.78 | 2、按照地区分类情况 | | 单位：万元 币种：人民币 | | --- | - ...

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. received an inquiry letter from the Shanghai Stock Exchange regarding its 2024 annual report, prompting the company to clarify issues related to its construction projects and investment performance, particularly concerning the erythritol production project which has underperformed financially due to market conditions [1][2]. Summary by Sections Construction Projects and Investment - In 2024, the company invested 1.43 billion yuan in fixed assets, intangible assets, and other long-term assets, marking a 106.99% increase year-on-year. The fixed assets reached 2.25 billion yuan, up 45.13%, while construction in progress surged by 357.58% to 1.33 billion yuan, primarily due to the Zhoushan Huakang project [1]. - The erythritol production project generated revenue of 72.44 million yuan in 2024 but incurred a gross loss of 1.72 million yuan, continuing to fall short of initial projections since its trial operation began in May 2022 [1][2]. Erythritol Project Details - The total investment for the erythritol project is estimated at 350.41 million yuan, with cumulative investment reaching 362.68 million yuan by the end of 2024. The project aims to produce 30,000 tons of high-purity erythritol annually [5][6]. - In 2024, the company produced 6,834.50 tons of erythritol, achieving a sales rate of 97.96%. The market price for erythritol was approximately 13,000 yuan per ton by December 2024 [6][11]. Market Conditions and Competition - The erythritol market has faced significant challenges, including declining prices and increased competition, leading to a supply-demand imbalance. The price of erythritol has been under pressure since 2023, with some manufacturers exiting the market [7][11]. - The company noted that the market for erythritol was initially promising, but the influx of new competitors and expanded capacities led to a significant drop in prices, affecting profitability [7][11]. Inventory and Trade Business - By the end of 2024, the company's inventory reached 697 million yuan, a 147.26% increase year-on-year, primarily due to increased raw material reserves for the Zhoushan project. The raw materials accounted for 448 million yuan, up 385.15% [15][16]. - The cash flow from trade business payments was 1.15 billion yuan, reflecting a 198.58% increase, driven by the anticipated demand for corn from the Zhoushan project [15][16].